28283889|t|CF3DODA-Me induces apoptosis, degrades Sp1, and blocks the transformation phase of the blebbishield emergency program
28283889|a|Cancer stem cells are capable of undergoing cellular transformation after commencement of apoptosis through the blebbishield emergency program in a VEGF - VEGFR2 - dependent manner. Development of therapeutics targeting the blebbishield emergency program would thus be important in cancer therapy. Specificity protein 1 (Sp1) orchestrates the transcription of both VEGF and VEGFR2; hence, Sp1 could act as a therapeutic target. Here, we demonstrate that CF3DODA-Me induced apoptosis, degraded Sp1, inhibited the expression of multiple drivers of the blebbishield emergency program such as VEGFR2, p70S6K, and N-Myc through activation of caspase-3, inhibited reactive oxygen species; and inhibited K-Ras activation to abolish transformation from blebbishields as well as transformation in soft agar. These findings confirm CF3DODA-Me as a potential therapeutic candidate that can induce apoptosis and block transformation from blebbishields.
28283889	0	10	CF3DODA-Me	T121	C1254351
28283889	11	18	induces	T169	C0205263
28283889	19	28	apoptosis	T043	C0162638
28283889	30	38	degrades	T169	C0243125
28283889	39	42	Sp1	T116,T123	C0080245
28283889	48	54	blocks	T169	C0332206
28283889	59	73	transformation	T043	C0040682
28283889	87	117	blebbishield emergency program	T043	C0007613
28283889	118	135	Cancer stem cells	T025	C1956422
28283889	162	185	cellular transformation	T046	C1510411
28283889	192	204	commencement	T079	C0439659
28283889	208	217	apoptosis	T043	C0162638
28283889	230	260	blebbishield emergency program	T043	C0007613
28283889	266	270	VEGF	T116,T123	C1256770
28283889	273	279	VEGFR2	T116,T192	C0378796
28283889	282	291	dependent	T080	C0851827
28283889	300	311	Development	T169	C1527148
28283889	315	327	therapeutics	T061	C0087111
28283889	328	337	targeting	T043	C0599894
28283889	342	372	blebbishield emergency program	T043	C0007613
28283889	400	414	cancer therapy	T061	C0920425
28283889	416	437	Specificity protein 1	T116,T123	C0080245
28283889	439	442	Sp1	T116,T123	C0080245
28283889	461	474	transcription	T045	C0040649
28283889	483	487	VEGF	T028	C1823619
28283889	492	498	VEGFR2	T028	C1334306
28283889	507	510	Sp1	T116,T123	C0080245
28283889	526	537	therapeutic	T169	C0039798
28283889	572	582	CF3DODA-Me	T121	C1254351
28283889	583	590	induced	T169	C0205263
28283889	591	600	apoptosis	T043	C0162638
28283889	602	610	degraded	T169	C0243125
28283889	611	614	Sp1	T116,T123	C0080245
28283889	616	625	inhibited	T080	C0311403
28283889	630	640	expression	T045	C1171362
28283889	668	698	blebbishield emergency program	T043	C0007613
28283889	707	713	VEGFR2	T116,T192	C0378796
28283889	715	721	p70S6K	T116,T126	C0073337
28283889	727	732	N-Myc	T116,T123	C0079885
28283889	741	751	activation	T052	C1879547
28283889	755	764	caspase-3	T116,T126	C0291573
28283889	766	775	inhibited	T080	C0311403
28283889	776	799	reactive oxygen species	T123,T196	C0162772
28283889	805	814	inhibited	T080	C0311403
28283889	815	820	K-Ras	T116,T126	C0079973
28283889	821	831	activation	T052	C1879547
28283889	835	842	abolish	T169	C0332206
28283889	843	857	transformation	T043	C0040682
28283889	863	876	blebbishields	T026	C0243092
28283889	888	902	transformation	T043	C0040682
28283889	906	915	soft agar	T109,T121,T130	C0001771
28283889	932	939	confirm	T033	C0750484
28283889	940	950	CF3DODA-Me	T121	C1254351
28283889	956	965	potential	T080	C3245505
28283889	966	977	therapeutic	T169	C0039798
28283889	978	987	candidate	T121	C1254351
28283889	997	1003	induce	T169	C0205263
28283889	1004	1013	apoptosis	T043	C0162638
28283889	1018	1023	block	T169	C0332206
28283889	1024	1038	transformation	T043	C0040682
28283889	1044	1057	blebbishields	T026	C0243092